The Centre For Cognitive Neuroimaging (CCNi) To Acquire A TRIUX™ neo
MEGIN is pleased to announce the acquisition of a TRIUX™ neo by The Centre For Cognitive Neuroimaging (CCNi), at the Institute for Neuroscience and Psychology at the University of Glasgow. This research facility will continue its role as the only MEG site in Scotland, continuously supporting neuroimaging related research.
The CCNi is a highly respected institution, bringing a multidisciplinary effort to innovate and bring new cognitive neuroimaging techniques to studies of the human brain. The CCNi aims to elevate the precision of non-invasive neuroimaging and brain stimulation, often applying multimodal imaging with MEG, fMRI, EEG and TMS.
Created in 2008 with investment from the University of Glasgow, the Scottish Research Infrastructure Fund (SRIF) and Wolfson, the CCNi has made significant scientific contributions. In the years spanning 2008-2019, researchers at the CCNi have published more than 497 papers, resulting in 16,523 citations.
The TRIUX™ neo will be utilized for advanced research purposes, and at MEGIN we look forward to seeing the studies that the TRIUX™ neo’s MEG technology can help facilitate.
These efforts will be led and supported by Professor Philippe Schyns, Head of the Institute for Neuroscience and Psychology, and Dr. Satu Palva, Professor in Magnetoencephalography, as well as others from the CCNi. The team were awarded a grant from the Wellcome Trust from 2020-2025 for a TRIUX™ neo for advancing multi-modal neuroimaging techniques in Scotland.
“One of the major scientific goals of the research carried out in the CCNi is to unravel how information is communicated and represented in the brain across the meso- and macro-scales with focus on neuronal oscillations and functional networks of the brain. With the superior precision and excellent signal quality of TRIUX™ neo, MEG will permit the mapping of oscillatory brain activity and functional networks of the brain at excellent hereto best possible spatial (anatomical) precision. TRIUX™ neo would leverage our understanding of their significance as substrate of cognition and behaviour and further support this strategic research area of the CCNi,” said Professor Philippe Schyns and Dr. Palva.
The TRIUX™ neo provides access to patients for the most precise information currently available on the market for functional brain mapping. MEG is a highly sensitive technology that can accurately detect and localize neural events that are generated in the brain with millimeter accuracy and millisecond resolution. It is completely silent and non-invasive.
MEG is used clinically to support clinical outcomes for pre-surgical evaluation in epilepsy and brain tumors. It is also applied in clinical research, for example in studies focusing on Alzheimer’s disease, Parkinson’s disease, Autism, and Traumatic Brain Injuries (TBI).
“We are excited to partner with CCNi and have MEGIN’s technology help to facilitate cutting-edge research,” concluded John Fulford, Managing Director, MEGIN OY.